« Previous  |  Next »

Cancer Drugs May Not Cure Pfizer

In recent years, companies like Pfizer have put more targeted cancer drugs into trials than ever before. The drugs aim at one or more defective growth promoting genes inside tumor cells. Companies hope to duplicate the enormous success of drugs like ...

From ROBERT LANGRETH, Forbes,  12 Mar 2010

Related Topics: Pfizer Inc.,  Jonathan Lewis,  Novartis,  Merck & Company, Inc.

Pfizer's Lemons

When it comes to shopping around for new drugs from biotech partners, Pfizer is a bit like a naive used car buyer. It seems to pay a lot of attention to the gloss on the surface, and not enough to whether the engine inside will work. How else can you ...

From ROBERT LANGRETH, Forbes,  10 Mar 2010

Related Topics: Pfizer Inc.,  University of Southern California,  Food and Drug Administration

A Ray Of Hope For Medivation

Medivation shares are down and out after its Alzheimer's drug Dimebon bombed in its first big trial. But the drug may not be completely dead yet, says University of Southern California Alzheimer's expert Lon Schneider. He points to a small ray of hope ...

From ROBERT LANGRETH, Forbes,  4 Mar 2010

Related Topics: University of Southern California,  Pfizer Inc.

Medivation Alzheimer's Drug Was Hyped

Shares of Medivation plunged 67% today after the Alzheimer's drug it was developing with Pfizer failed abysmally in its first big clinical trial. Investors and some Alzheimer's researchers had had high hope that the drug, called Dimebon, would be the ...

From ROBERT LANGRETH, Forbes,  3 Mar 2010

Related Topics: University of Southern California,  Pfizer Inc.,  UT Southwestern Medical Center

The Mathematics Of Cancer

Larry Norton sees some of the toughest cases as deputy physician-in-chief for breast cancer at Memorial Sloan-Kettering Cancer Center. He has access to the most advanced imaging machines, the best surgeons and numerous new tumor-fighting drugs. But ...

From ROBERT LANGRETH, Forbes,  25 Feb 2010

Related Topics: Memorial Sloan-Kettering Cancer Center,  University of Rochester,  Columbia University,  National Cancer Institute,  Richard Simon

Novartis' Great Weekend

Now comes the harder part--getting the MS drug and the new leukemia drug use approved by the Food and Drug Administration. The MS drug, FTY720 or fingolimod, would be the first pill  approved for the disease. However, there are likely to be serious ...

From ROBERT LANGRETH, Forbes,  22 Feb 2010

Related Topics: Novartis,  Food and Drug Administration

Asthma drugs get stiff new warnings

Four years ago we wrote about the controversy over whether one of the ingredients in GlaxoSmithkline's popular asthma inhaler Advair can in rare cases boost the risk of asthma-related hospitalization or death (See Trouble Breathing). The debate ...

From ROBERT LANGRETH, Forbes,  18 Feb 2010

Related Topics: Food and Drug Administration,  Novartis,  Merck & Company, Inc.,  AstraZeneca PLC

Big Pharma's Best Chief Steps Down

Novartis Chief Executive Daniel Vasella likes to shake his company up every few years. Now he's reshuffling himself. Vasella, just 56 years old, stunned investors on Tuesday by saying he was stepping down as chief executive effective Feb. 1 and ...

From ROBERT LANGRETH, Forbes,  26 Jan 2010

Related Topics: Novartis,  Daniel Vasella,  Stanford University

GlaxoSmithkline's Malaria Plan: Limit Profits, Open Labs

Drug companies get bashed for not doing enough for killer diseases like malaria that hit the developing world even as they spent hugely on lifestyle drugs for wealthy folks. GlaxoSmithKline ( GSK - news - people ) Chief Executive Andrew Witty ...

From ROBERT LANGRETH, Forbes,  20 Jan 2010

Related Topics: GlaxoSmithKline Inc,  Emory University,  Alnylam Pharmaceuticals, Inc.,  Council on Foreign Relations,  Merck & Company, Inc.

Monsanto Investigation Heats Up

Seed giant Monsanto is Forbes' company of the year, thanks to its innovative  soybean and corn seeds that  resist weeds and pests and make life much easier for farmers. (See: The Planet Versus Monsanto: ...

From ROBERT LANGRETH, Forbes,  15 Jan 2010

Related Topics: U.S. Department of Justice

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry